TAMPA, Fla., Jan. 30, 2017 -- Odyssey Marine Exploration, Inc. (Nasdaq:OMEX), a pioneer in the field of deep-ocean exploration, announced today that on January 30, 2017, the Company received a letter from The NASDAQ Stock Market LLC (“Nasdaq”) indicating that the Company is in compliance with all applicable listing standards for continued listing on The Nasdaq Capital Market, including the $35 million market value of listed securities requirement. As a result, the Company’s securities will continue to be listed on Nasdaq, and the hearing before the Nasdaq Hearings Panel has been cancelled by Nasdaq.
About Odyssey Marine Exploration
Odyssey Marine Exploration, Inc. (Nasdaq:OMEX) is engaged in deep-ocean exploration using innovative methods and state of-the-art technology. The company has numerous projects in various stages of development around the world from both our own portfolio as well as through third-party contracts. For additional details, please visit www.odysseymarine.com.
Forward Looking Information
Odyssey Marine Exploration believes the information set forth in this Press Release may include "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. Certain factors that could cause results to differ materially from those projected in the forward-looking statements are set forth in "Risk Factors" in Part I, Item 1A of the Company's Annual Report on Form 10-K for the year ended December 31, 2015, which was filed with the Securities and Exchange Commission on March 30, 2016.
MEDIA CONTACT: Liz Shows Odyssey Marine Exploration, Inc. (813) 876-1776 x 2562 [email protected]


Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
FDA Approves Mitapivat for Anemia in Thalassemia Patients 



